HR-QOL of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder (MIBC) patients undergoing SOC treatment in Japan

HR-QOL of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder (MIBC) patients undergoing SOC treatment in Japan - HR-QOL of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder (MIBC) patients undergoing SOC treatment in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056273

Enrollment

350

Registered

2024-11-29

Start date

2024-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Each patient must satisfy the following criteria to be eligible for data collection in this study: ?Patients are male or female aged 18 years and older ?Patients have a confirmed diagnosis of NMIBC or MIBC For NMIBC patients (either one of the following): ?A) Currently receiving or have received the last BCG therapy within the last 6 months. ?B) BCG-unresponsive and currently receiving or have received the last RC therapy within the last 6 months. For MIBC patients (either one of the following): ?A) Have previously undergone complete RC within the last 6 months. ?B) Currently receiving or have received the last bladder preservation therapy (combination of TURBT, chemotherapy, and/or radiotherapy) within the last 6 months.

Exclusion criteria

Exclusion criteria: Potential patients who meet any of the following criteria will not be eligible for this study: 1.Patients with metastatic bladder cancer or any other concurrent cancer 2.Patients who have undergone partial RC or a combination of BCG, RC and TMT

Design outcomes

Primary

Measure	Time frame
EORTC QLQ-C30 scores, EORTC QLQ-NMIBC24/ BLM30 scores, and DCS scores	—

Secondary

Measure	Time frame
EORTC QLQ-C30, EORTC QLQ-NMIBC24/ BLM30, and DCS scores in subgroups	—

Countries

Japan

Contacts

Public ContactHikaru Onishi

INTAGE Healthcare Inc. Value & Access Department

onishi.46072@intage.com050-3640-3110

Outcome results